Advanced basal cell carcinoma of the skin: Targeting the hedgehog pathway

Current Opinion in Oncology

Volumn 25, Issue 3, 2013, Pages 218-223

  Sekulic, Aleksandar ^a   Mangold, Aaron R ^a   Northfelt, Donald W ^a   Lorusso, Patricia M ^b  

^a MAYO CLINIC   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

advanced basal cell carcinoma; hedgehog pathway; patched; smoothened; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; N (3 METHOXYBENZYL) 3,3 DIMETHYL N [1 (3,4 METHYLENEDIOXYBENZYL) 2 (1 PIPERAZINYLCARBONYL) 4 PYRROLIDINYL]BUTYRAMIDE; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG; VISMODEGIB;

ALOPECIA; APPETITE; BASAL CELL CARCINOMA; CANCER RESEARCH; CANCER THERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; INHIBITION KINETICS; MUSCLE DISEASE; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; HEDGEHOG PROTEINS; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84876295412     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835ff438     Document Type: Review

References (45)

1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of non-melanoma skin cancer in the United States, 2006. Arch Dermatol 2010; 146:283-287.
2. Donaldson MR, Coldiron BM. No end in sight: the skin cancer epidemic continues. Semin Cutaneous Med Surg 2011; 30:3-5.
3. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol 2003; 48:425-429.
4. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. Br J Dermatol 2006; 155:401-407
5. Notice of Availability of 10th Report on Carcinogenesis (http://ntp.niehs.nih. gov/go/11280), Federal Register 2002; 67:77283-5.
6. Malone JP, Fedok FG, Belchis DA, Maloney ME. Basal cell carcinoma metastatic to the parotid: report of a new case and review of the literature. Ear Nose Throat J 2000; 79:511-515; 8-9.
7. Lo JS, Snow SN, Reizner GT, et al. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24:715-719.
8. Weinstock MA, Still JM. Assessing current treatment options for patients with severe/advanced basal cell carcinoma. Semin Cutaneous Med Surg 2011; 30:S10-S13.
9. Moeholt K, Aagaard H, Pfeiffer P, Hansen O. Platinum-based cytotoxic therapy in basal cell carcinoma: a review of the literature. Acta Oncol 1996; 35:677-682.
10. Jaal J, Putnik K. Induction cisplatin-based chemotherapy and following radiotherapy in locally advanced basal cell carcinoma of the skin. Acta Oncol 2012; 51:952-954.
11. Gailani MR, Stahle-Backdahl M, Leffell DJ, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nature Genet 1996; 14:78-81.
12. Aszterbaum M, Rothman A, Johnson RL, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Investig Dermatol 1998; 110:885-888.
13. Ingham PW, Placzek M. Orchestrating ontogenesis: variations on a theme by sonic hedgehog. Nature Rev Genet 2006; 7:841-850.
14. Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30:303-312.
15. Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 1960; 262:908-912.
16. Gailani MR, Bale SJ, Leffell DJ, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992; 69:111-117.
17. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841-851.
18. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nature Rev Cancer 2008; 8:743-754.
19. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391:90-92.
20. Bryden MM, Evans HE, Keeler RF. Cyclopia in sheep caused by plant teratogens. J Anatomy 1971; 110:507.
21. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Develop 2002; 16:2743-2748.
22. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000; 406:1005-1009.
23. Tabs S, Avci O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur J Dermatol 2004; 14:96-102.
24. Tang T, Tang JY, Li D. Targeting superficial or nodular Basal cell carcinoma with topically formulated small molecule inhibitor of smoothened. Clin Cancer Res 2011; 17:3378-3387.
25. Gupta S, Takebe N, Lorusso P. Targeting the Hedgehog pathway in cancer. Therapeut Adv Med Oncol 2010; 2:237-250
26. National Institutes of Health Clinical Trialsgov Available at: http://clinicaltrials gov.
27. Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutaneous Med Surg 2011; 30:S14-S18.
28. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361:1164-1172.
29. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366:2171-2179.
30. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 2012; 366:2180-2188.
31. Atwood SX, Chang AL, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol 2012; 199:193-197.
32. Teperino R, Amann S, Bayer M, et al. Hedgehog partial agonism drives Warburg-like metabolism in muscle and brown fat. Cell 2012; 151:414-426.
33. LoRusso PM, Rudin CM, Reddy JC, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17:2502-2511.
34. Lorusso PM, Piha-Paul SA, Mita M, et al. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. Cancer Chemother Pharmacol 2013; 71:193-202
35. wwwclinicaltrialsgov identifier NCT01201915
36. wwwclinicaltrialsgov identifier NCT01556009.
37. Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res 2011; 71:5057-5061.
38. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361:1173-1178.
39. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009; 326:572-574.
40. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013; 23:23-34.
41. Rudin CM. Vismodegib. Clinical Cancer Res 2012; 18:3218-3222.
42. Chang AL, Oro AE. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch Dermatol 2012; 1-2.
43. Kasper M, Jaks V, Hohl D, Toftgard R. Basal cell carcinoma: molecular biology and potential new therapies. J Clin Investig 2012; 122:455-463.
44. Skvara H, Kalthoff F, Meingassner JG, et al. Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor. J Investig Dermatol 2011; 131:1735-1744
45. www.clinicaltrialsgov.identifier NCT01543581.